Innovative platform to develop completely human-derived antibodies for the treatment of multiple cancer types.
Grid Therapeutics is an emerging bio-therapeutic company located in Durham, North Carolina. Grid’s research and development efforts are in the area of cancer therapeutics, applying an innovative platform to develop completely human-derived antibodies for the treatment of multiple cancer types. Their first asset used this novel approach to produce a high-affinity antibody derived from single human B cells that inhibits an essential tumor cell-protective protein, resulting in rapid tumor cell death with no known side-effects. This first-in-class antibody is being manufactured and will enter phase 1 clinical trials by the end of 2018.